Deltagen Announces 187 Potential Genomic Drug Targets in DeltaBase

Apr 03, 2001, 01:00 ET from Deltagen, Inc.

    MENLO PARK, Calif., April 3 /PRNewswire/ -- Deltagen, Inc. (Nasdaq: DGEN),
 a genomics and biotechnology company, announced today that it delivered the
 third quarterly release of its mammalian gene function data to its current
 DeltaBase(TM) subscribers.  DeltaBase is a database containing functional
 information about genes and their in vivo mammalian roles.
     DeltaBase currently includes 187 potential genomic drug targets. Through
 detailed, in vivo analyses of the mouse, a closely related mammalian model to
 humans, Deltagen has identified phenotypes and potential drug targets in many
 key disease areas, including cancer, diabetes, inflammation, immune system
 disorders, anxiety, depression, pain, schizophrenia, fertility and vision.
     "Genomics has promised many drug development opportunities to the
 pharmaceutical industry, however, the vast majority represent poorly validated
 drug targets.  Our technology platform provides the data to rapidly assess the
 potential of genes as drug targets and allows companies to concentrate their
 efforts on highly validated targets," said William Matthews, Ph.D., president
 and chief executive officer at Deltagen.  "Our generation and delivery of
 DeltaBase data on 187 mammalian genes is an example of the speed, depth and
 scale of this technology," continued Dr. Matthews.
     With the sequencing of the human genome, understanding gene function in
 mammalian models is the next critical step of research and development efforts
 to identify and validate genes for drug discovery.  The mouse has genes,
 biochemical pathways, physiology and organ functions that are closely related
 to humans and is the single most familiar mammalian model organism to
 researchers.  With its ability to be genetically modified, the mouse has
 become the major experimental system of choice to study mammalian gene
 function and the genetics and pathway biology of human diseases.
     The information contained in DeltaBase provides scientists with the
 ability to initiate, validate or modify drug discovery programs based upon
 information and relationships between gene targets and disease indications.
 DeltaBase contains the critical functional and phenotypic information for
 genes that have been chosen for their ability to be useful targets for drug
 discovery.
     Deltagen is a genomic and biotechnology company headquartered in Menlo
 Park, California, that provides data to pharmaceutical and biotechnology
 companies on the function, role and disease relevance of mammalian genes. This
 information may facilitate the discovery and validation of drug targets to
 advance the development of new genomic-based medicines. Deltagen's principal
 product, DeltaBase(TM) provides a database of in vivo derived, mammalian gene
 function information.  In addition, the Company offers a program dedicated to
 determining the function of secreted proteins. Under this program, the company
 undertakes the discovery and development of secreted protein biotechnology
 drug candidates internally or in collaboration with other parties.  The
 Company has recently exclusively licensed a potential treatment for Acute
 Myelogenous Leukemia (AML) that targets the CD123 antigen. Deltagen's current
 customers include GlaxoSmithKline plc, Merck Inc., Pfizer Inc., and
 Schering-Plough Research Institute. The Company's current DeltaBase
 subscribers are GlaxoSmithKline plc and Pfizer Inc.
     This press release contains forward looking statements that are subject to
 risks and uncertainties that could cause actual results to differ materially
 from those set forth in the forward-looking statements, including
 uncertainties related to product and drug development, uncertainties related
 to the need for regulatory or other government approvals, the Company's
 patents and other intellectual property, dependence on proprietary technology,
 uncertainty of market acceptance of the company's products, uncertainties
 related to business opportunities, the receipt of future payments, including
 milestones and royalties, the continuation of customer relationships cited in
 the risk factors sections of the Company's Annual Report on Form  10-K filed
 with the Securities and Exchange Commission and the Company's other securities
 filings with the Commission. These forward-looking statements speak only as of
 the date hereof. The Company disclaims any intent or obligation to update
 these forward-looking statements.
 
 

SOURCE Deltagen, Inc.
    MENLO PARK, Calif., April 3 /PRNewswire/ -- Deltagen, Inc. (Nasdaq: DGEN),
 a genomics and biotechnology company, announced today that it delivered the
 third quarterly release of its mammalian gene function data to its current
 DeltaBase(TM) subscribers.  DeltaBase is a database containing functional
 information about genes and their in vivo mammalian roles.
     DeltaBase currently includes 187 potential genomic drug targets. Through
 detailed, in vivo analyses of the mouse, a closely related mammalian model to
 humans, Deltagen has identified phenotypes and potential drug targets in many
 key disease areas, including cancer, diabetes, inflammation, immune system
 disorders, anxiety, depression, pain, schizophrenia, fertility and vision.
     "Genomics has promised many drug development opportunities to the
 pharmaceutical industry, however, the vast majority represent poorly validated
 drug targets.  Our technology platform provides the data to rapidly assess the
 potential of genes as drug targets and allows companies to concentrate their
 efforts on highly validated targets," said William Matthews, Ph.D., president
 and chief executive officer at Deltagen.  "Our generation and delivery of
 DeltaBase data on 187 mammalian genes is an example of the speed, depth and
 scale of this technology," continued Dr. Matthews.
     With the sequencing of the human genome, understanding gene function in
 mammalian models is the next critical step of research and development efforts
 to identify and validate genes for drug discovery.  The mouse has genes,
 biochemical pathways, physiology and organ functions that are closely related
 to humans and is the single most familiar mammalian model organism to
 researchers.  With its ability to be genetically modified, the mouse has
 become the major experimental system of choice to study mammalian gene
 function and the genetics and pathway biology of human diseases.
     The information contained in DeltaBase provides scientists with the
 ability to initiate, validate or modify drug discovery programs based upon
 information and relationships between gene targets and disease indications.
 DeltaBase contains the critical functional and phenotypic information for
 genes that have been chosen for their ability to be useful targets for drug
 discovery.
     Deltagen is a genomic and biotechnology company headquartered in Menlo
 Park, California, that provides data to pharmaceutical and biotechnology
 companies on the function, role and disease relevance of mammalian genes. This
 information may facilitate the discovery and validation of drug targets to
 advance the development of new genomic-based medicines. Deltagen's principal
 product, DeltaBase(TM) provides a database of in vivo derived, mammalian gene
 function information.  In addition, the Company offers a program dedicated to
 determining the function of secreted proteins. Under this program, the company
 undertakes the discovery and development of secreted protein biotechnology
 drug candidates internally or in collaboration with other parties.  The
 Company has recently exclusively licensed a potential treatment for Acute
 Myelogenous Leukemia (AML) that targets the CD123 antigen. Deltagen's current
 customers include GlaxoSmithKline plc, Merck Inc., Pfizer Inc., and
 Schering-Plough Research Institute. The Company's current DeltaBase
 subscribers are GlaxoSmithKline plc and Pfizer Inc.
     This press release contains forward looking statements that are subject to
 risks and uncertainties that could cause actual results to differ materially
 from those set forth in the forward-looking statements, including
 uncertainties related to product and drug development, uncertainties related
 to the need for regulatory or other government approvals, the Company's
 patents and other intellectual property, dependence on proprietary technology,
 uncertainty of market acceptance of the company's products, uncertainties
 related to business opportunities, the receipt of future payments, including
 milestones and royalties, the continuation of customer relationships cited in
 the risk factors sections of the Company's Annual Report on Form  10-K filed
 with the Securities and Exchange Commission and the Company's other securities
 filings with the Commission. These forward-looking statements speak only as of
 the date hereof. The Company disclaims any intent or obligation to update
 these forward-looking statements.
 
 SOURCE  Deltagen, Inc.